Trimetazidine administered after successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes, according to results of the ATPCI ...
DUBLIN--(BUSINESS WIRE)--The "Angina Pectoris: Global Drug Forecast and Market Analysis to 2028" report has been added to ResearchAndMarkets.com's offering. This report focuses on the following forms ...
A compound designed to prevent chest pains in heart patients has shown promising results in animal studies, say scientists. In the second issue of the British Journal of Pharmacology to be published ...
CV Therapeutics Angina Drug Fails in New Heart Disease Test PALO ALTO, Calif., March 6 -- CV Therapeutics, Inc. announced today that an analysis of unblinded data from the MERLIN TIMI-36 study of ...
NEW YORK, March 6 (Reuters) - CV Therapeutics Inc. said on Tuesday its angina drug Ranexa was not effective in a study of acute and long-term treatment of patients with a type of heart disease known ...
An angina drug called trimetazidine has been in the news lately connected to the 2022 Winter Olympics, but it's been on the radar of anti-doping authorities for years. Russian media reported that the ...
A new drug ranolazine is a safe and effective treatment for chronic stable angina and adds to the treatment options for patients with this condition. The treatment is discussed in a New Drug Class ...
A drug used in the clinical treatment of angina symptoms also has an anti-inflammatory effect and reduces atherosclerotic plaques in blood vessels - thereby reducing the risk of heart attack or stroke ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results